Mono-Cedocard Retard (Isosorbide Mononitrate)

Isosorbide Mononitrate, the active ingredient in Mono-Cedocard Retard, is an organic nitrate presented as a prolonged‑release tablet for oral use. It is employed to manage angina pectoris and chronic heart failure in adult patients.

GNH USA supplies Mono-Cedocard Retard as a licensed, GMP‑qualified, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures product quality through rigorous quality‑control testing, adheres to EU regulatory standards, and provides reliable logistics, regulatory support and consistent batch availability across multiple markets.

Isosorbide Mononitrate is used in the management of cardiovascular conditions that reduce myocardial oxygen demand.

- Angina pectoris: decreases frequency and severity of chest pain episodes. - Chronic heart failure: improves exercise tolerance and reduces symptoms of dyspnea. - Stable angina: provides prophylactic relief of effort‑induced angina attacks.

Isosorbide Mononitrate may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache: throbbing pain often occurring shortly after dosing. - Dizziness: sensation of light‑headedness or imbalance. - Flushing: warm sensation with reddening of skin. - Hypotension: low blood pressure, sometimes accompanied by faintness. - Nausea: mild stomach upset. - Palpitations: awareness of irregular heartbeats.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Syncope: sudden loss of consciousness. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Stevens‑Johnson syndrome: rare severe skin reaction.

When prescribing Isosorbide Mononitrate, clinicians should observe several safety considerations.

- Monitor blood pressure: check for excessive lowering after initiation. - Avoid abrupt discontinuation: taper to prevent rebound angina. - Use caution in hepatic impairment: dose may need adjustment. - Assess concomitant PDE5 inhibitor use: combined effect can cause profound hypotension. - Review patient’s antihypertensive regimen: risk of additive blood pressure reduction. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Isosorbide Mononitrate interacts with several drug classes; awareness of these interactions helps prevent adverse events.

Major Interactions (Avoid): - Other nitrates (e.g., nitroglycerin): can cause dangerous hypotension. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): risk of severe blood pressure fall. - Antihypertensive agents combined with high doses: may lead to excessive hypotension.

Moderate Interactions (Monitor Closely): - Beta‑blockers: additive blood pressure‑lowering effect. - Diuretics: may enhance orthostatic hypotension. - Alcohol: can increase vasodilatory response and dizziness. - Calcium channel blockers: potential for enhanced hypotensive effect.